

Termination of coverage

13 April 2017

Edison Investment Research is terminating coverage on Epigenomics (ECX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Director of research

Neil Shah +44 (0)20 3077 5724 nshah@edisongroup.com Edison website

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the <u>Financial Conduct Authority</u>. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered to the New Zealand Financial Service Providers Register (FSP number 247505) and is regulated and/or generic financial adviser services only. Edison Investment Research Inc (Edison NZ) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Research Limited [4794244]. <u>www.edisongroup.com</u>

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publication. The securities described in the Investment Research age in all jurisdictions or to certain categories of investors. This research in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our since opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers? (or underwrite any securities mentioned or in the topic of this document. This document his networed for the topic strain as a socitation or investment tesearch and is not subject to any prohibition on dealing ahead of the dissemination of investment tesearch. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment to theore of this document has not been prepared in an accordance with the legisle engineed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The document is intended to by, selicitation or

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US Sydney +61 (0)2 8249 8342 Level 12, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia